Comparative Pharmacology
Head-to-head clinical analysis: ISOFLURANE versus SUPRANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOFLURANE versus SUPRANE.
ISOFLURANE vs SUPRANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isoflurane is a general inhalation anesthetic that acts as a positive allosteric modulator of GABA-A receptors and glycine receptors, and inhibits excitatory receptors such as NMDA and AMPA receptors. It potentiates inhibitory neurotransmission and depresses excitatory neurotransmission, leading to anesthesia, amnesia, and muscle relaxation.
Suprane (desflurane) is a volatile general anesthetic that potentiates GABA-A receptor activity and inhibits NMDA receptor function, leading to neuronal hyperpolarization and depression of central nervous system activity.
Induction: 1-3% in oxygen or oxygen/nitrous oxide mixture via inhalation; Maintenance: 0.5-2% in oxygen or oxygen/nitrous oxide mixture via inhalation.
Induction: 0.5-3% inspired concentration in oxygen or oxygen/nitrous oxide mixture; Maintenance: 0.5-2% inspired concentration. Administered via inhalation using a calibrated vaporizer.
None Documented
None Documented
Clinical Note
moderateIsoflurane + Torasemide
"The risk or severity of adverse effects can be increased when Isoflurane is combined with Torasemide."
Clinical Note
moderateIsoflurane + Etacrynic acid
"The risk or severity of adverse effects can be increased when Isoflurane is combined with Etacrynic acid."
Clinical Note
moderateIsoflurane + Furosemide
"The risk or severity of adverse effects can be increased when Isoflurane is combined with Furosemide."
Clinical Note
moderateIsoflurane + Bumetanide
Terminal elimination half-life is approximately 2.5 to 5 hours. Context: The context-sensitive half-time varies with duration of anesthesia; for short procedures (<1 hour), half-life is about 2-4 minutes, but for prolonged anesthesia, it can be 30-60 minutes due to redistribution from fat stores.
Context-sensitive half-life: 2-5 minutes after brief administration; prolonged to 20-40 minutes after prolonged administration due to slow release from fat stores.
Primarily eliminated via exhalation through the lungs (>99%). Less than 1% undergoes hepatic metabolism to trifluoroacetic acid and fluoride ions, which are excreted renally.
Primarily eliminated by the lungs with minimal metabolism (<5%). Less than 0.2% of the absorbed dose is excreted renally as unchanged drug.
Category C
Category C
Inhalational Anesthetic
Inhalational Anesthetic
"The risk or severity of adverse effects can be increased when Isoflurane is combined with Bumetanide."